Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

McNEIL AD CLAIM THAT IBUPROFEN SIDE EFFECT PROFILE IS "INDISTINGUISHABLE" from aspirin, in cluding the likelihood of stomach upset, is being challenged by American Home Products (AHP) in a June 24 complaint filed in New York Federal Court. AHP alleges that the objective of McNeil's latest Tylenol ad campaign is to "tar the OTC ibuprefen products with the same stomach upset and other side effect safety concerns that McNeil has heretofore directed against aspirin-based analgesic products." The suit alleges that McNeil's advertising is contrary to the findings of FDA that "the safety record of ibuprofen is on a par with Tylenol's, and that, in fact, OTC ibuprofen products such as Advil would be expected to have fewer side effects than Extra-Strength Tylenol or 'extra-strength' doses of aspirin." The complaint quotes FDA's Summary Basis of Approval for OTC ibuprofen. The FDA summary said that "at 'extra strength' doses the incidence of adverse effects (applicable) to aspirin and acetaminophen would be expected to be higher" than OTC ibuprofen, AHP noted. One of the ads AHP objects to is included in a brochure for health care professionals which claims Extra-Strength Tylenol provides "superior non-Rx analgesia" and is "first-line therapy" for general aches and pains, headache, sprains and strains, musculoskeletal pain and dental pain. Under the heading "sprains and strains" the ad notes that "3.6 gm aspirin daily is needed for true anti-inflammatory effect" while "at least 1,600 mg daily of ibuprofen is required for clinical demonstrable antiinflammatory effect." The ad further states that "Extra-Strength Tylenol plus local therapy usually provides optimal pain relief." AHP contends the ad makes "the false and misleading claim that Extra-Strength Tylenol has an anti-inflammatory effect." AHP also objects to McNeil's statement that Tylenol is the analgesic of choice among hospitals. "Such advertising falsely and misleadingly represents that hospitals trust or prefer Tylenol over other acetaminophen brands, such as Anacin-3, because Tylenol is superior to those brands in safety or effectiveness." The company declares: "McNeil never informs consumers in its advertising that the reason Tylenol is chosen by hospitals over other brands of acetaminophen has nothing to do with any alleged superiority of Tylenol over other acetaminophen brands but rather the low price at which Tylenol is offered by McNeil to hospitals for purchase or other considerations unrelated to safety or effectiveness." The complaint was filed jointly by the Washington, D.C. law firm Arnold & Porter and the New York firm Parker, Auspitz, Neesemann & Delehanty. AHP is seeking preliminary injunction against dissemination of the ads described in the complaint or similar ads, an award of profits, damages, costs and attorneys' fees and an order requiring McNeil to distribute corrective advertisements.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts